Q-omics provides the consensus-scored ICOSLG profile across patient tissues and cancer cell-line models. ICOSLG expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ICOSLG is differentially expressed in 3, with the highest sampling consensus in LIHC. Additionally, ICOSLG RNA expression shows 9,441 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, LIHC, and TGCT as cancer lineages where ICOSLG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ICOSLG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ICOSLG survival associations across molecular data types. ICOSLG RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ICOSLG RNA expression–survival associations across cancer types. High ICOSLG expression shows unfavorable associations in MESO, LGG, UVM and OV, but favorable associations in SCLC and CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify MESO as the clearest survival context for ICOSLG RNA expression.
This table summarizes ICOSLG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ICOSLG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ICOSLG shows lower tumor expression in KICH and KIRP and higher tumor expression in LIHC. The LIHC box plot shows higher ICOSLG RNA expression in tumor versus normal tissue (log2 FC = +0.210, t-test p = .001).
This table shows molecular features associated with ICOSLG in patient tissues and cancer cell lines. In patient samples, ICOSLG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ICOSLG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
